Miro Health signs first customer

Genentech has become Miro's first customer. Founded in 1976, and acquired by Roche in 2009, Genentech has pioneered methods of treating cancer and other ailments by harnessing the body’s native intelligence to eradicate disease rather than expose it to external toxins like chemotherapy. The success of Genentech’s approach, broadly referred to as ‘biotechnology’, attracted pharmaceutical heavy-weights and start-ups alike, resulting in a fiercely competitive space.

While the war with cancer is far from won, and many patients find no effective therapy, a growing number of patients are surviving and returning to work. A good number of them, particularly knowledge workers, face difficulty in the performance of their duties to the extent that they are forced to change jobs or reduce their level of responsibility. As a result, therapeutics developers are being forced to look beyond preservation of life to the quality of life preserved.

Measuring subtle changes in brain functions that yield significant impairment of higher-level work duties requires tools capable of measuring such changes. Miro Health’s high fidelity, whole-brain approach delivers measurement of nuanced performance changes associated with Cancer Related Cognitive Impairment (CRCI).


Recent Posts

See All

Solving the neurological puzzle of COVID-19

Miro Health and Johns Hopkins have teamed up to investigate how COVID-19 affects the brain. Doctors on the frontlines of COVID-19 have been reporting unusual symptoms ranging from loss of smell and ne

  • Frame 25
  • Frame 26
  • Frame 35
appstore-aaf345f67a67888a4c00c42b1f5d759

COMPANY

PRODUCT

QUESTIONS